Regulus Therapeutics Inc. announced that Simos Simeonidis, Ph.D., member of the Board of Directors, has stepped down from the Board, due to the time requirements of his recent appointment as co-Chief Executive Officer and co-Chief Investment Officer at Ally Bridge Group. His resignation was effective December 6, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.92 USD | 0.00% | -4.00% | +50.00% |
16/05 | Regulus Therapeutics Inc. Announces Promotion of Rekha Garg to Chief Medical Officer | CI |
09/05 | Regulus Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.00% | 13Cr | |
+10.79% | 12TCr | |
+11.65% | 11TCr | |
-6.20% | 2.39TCr | |
-3.55% | 2.16TCr | |
-11.32% | 1.9TCr | |
-13.41% | 1.63TCr | |
-40.50% | 1.7TCr | |
+6.64% | 1.41TCr | |
+31.84% | 1.2TCr |
- Stock Market
- Equities
- RGLS Stock
- News Regulus Therapeutics Inc.
- Regulus Therapeutics Inc. Announces Resignation of Simos Simeonidis as Board Member